Found 574 with Last Name = 'musch' and Initial = 'd' TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Merck Patent
US Patent
Merck Patent
US Patent
Affinity DataKi: 300nMAssay Description:Inhibition of the ion channel hErg (or Kv11.1) current causes QT interval prolongation resulting in potentially fatal ventricular tachyarrhythmia cal...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Merck Patent
US Patent
Merck Patent
US Patent
Affinity DataKi: 600nMAssay Description:Inhibition of the ion channel hErg (or Kv11.1) current causes QT interval prolongation resulting in potentially fatal ventricular tachyarrhythmia cal...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Merck Patent
US Patent
Merck Patent
US Patent
Affinity DataKi: 1.20E+3nMAssay Description:Inhibition of the ion channel hErg (or Kv11.1) current causes QT interval prolongation resulting in potentially fatal ventricular tachyarrhythmia cal...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Merck Patent
US Patent
Merck Patent
US Patent
Affinity DataKi: 2.50E+3nMAssay Description:Inhibition of the ion channel hErg (or Kv11.1) current causes QT interval prolongation resulting in potentially fatal ventricular tachyarrhythmia cal...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Merck Patent
US Patent
Merck Patent
US Patent
Affinity DataKi: 7.50E+3nMAssay Description:Inhibition of the ion channel hErg (or Kv11.1) current causes QT interval prolongation resulting in potentially fatal ventricular tachyarrhythmia cal...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Merck Patent
US Patent
Merck Patent
US Patent
Affinity DataKi: >1.00E+4nMAssay Description:Inhibition of the ion channel hErg (or Kv11.1) current causes QT interval prolongation resulting in potentially fatal ventricular tachyarrhythmia cal...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Merck Patent
US Patent
Merck Patent
US Patent
Affinity DataKi: >1.00E+4nMAssay Description:Inhibition of the ion channel hErg (or Kv11.1) current causes QT interval prolongation resulting in potentially fatal ventricular tachyarrhythmia cal...More data for this Ligand-Target Pair
Affinity DataIC50: 0.300nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 0.5nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 0.700nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 0.800nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 0.800nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 1.10nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 1.40nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 1.40nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 1.70nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 1.90nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 1.90nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 3.5nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:The inhibition of SHP2 by compounds of the invention was monitored using the surrogate substrate DiFMUP after protein activation by a peptide bearing...More data for this Ligand-Target Pair
